SOUTH SAN FRANCISCO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. HARP, a clinical-stage immuno-oncology company developing novel T cell engagers, announced today that AbbVie has notified the company that it will not exercise the exclusive license option of the parties’ Development and Option Agreement in connection with…Read More
Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie Harpoon Therapeutics NASDAQHARP
